Myeloma Investment Fund

About

Portfolio

Investor Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Myeloma Investment Fund's primary investment focus?

Myeloma Investment Fund primarily focuses on the Health Tech & Life Sciences sector, with both of its recorded portfolio companies, KAHR Medical and Nectin Therapeutics, operating in this area.

When did Myeloma Investment Fund make its first recorded investment?

Myeloma Investment Fund made its first recorded investment in November 2022.

Has Myeloma Investment Fund acted as a lead investor in any of its portfolio companies?

Yes, Myeloma Investment Fund was a lead investor in Nectin Therapeutics in May 2023.

What was Myeloma Investment Fund's most recent investment activity?

Myeloma Investment Fund's most recent investment activity was in May 2023, when it invested in Nectin Therapeutics.

Can you name a notable company in Myeloma Investment Fund's portfolio?

A notable company in Myeloma Investment Fund's portfolio is KAHR Medical, which has raised $118.27M since its founding in 2005.

What is the investment range for Myeloma Investment Fund, based on available data?

According to startupim data, Myeloma Investment Fund's recorded investment range is $12.5M - $12.5M, based on its investment in KAHR Medical.

How many new portfolio companies did Myeloma Investment Fund add in 2022?

Myeloma Investment Fund added one new portfolio company, KAHR Medical, in 2022.

How many new portfolio companies did Myeloma Investment Fund add in 2023?

Myeloma Investment Fund added one new portfolio company, Nectin Therapeutics, in 2023.